TOPIC

/ company

BeOne

The latest news and top stories on BeOne Medicines. Hong Kong-listed BeOne Medicines, formerly BeiGene, specialises in developing and selling innovative oncology products. Headquartered in Beijing China with global operations, they primarily serve cancer patients worldwide, addressing unmet medical needs. Notable for its rapid growth and pioneering advancements in immuno-oncology, the company's key products include the blood cancer drug zanubrutinib (Brukinsa) and the oncology drug tislelizumab (Tevimbra). BeOne Medicines anticipates significant net profit, reflecting its focus on transforming cancer treatment through cutting-edge research and global expansion.

China is attempting to boost the sales of at least five of its drugs to US$1 billion by 2030. Photo: Shutterstock

China’s private sector

China wants 5 innovative drugs with US$1b returns by 2030. Which might they be?

Beijing is attempting to have at least five pharmaceutical products with annual global sales of more than US$1 billion.

10 Oct 2026 - 8:00AMvideocam

China stock market

Investors pivot from ‘single bet’ China view to target individual winners: DBS

24 Sep 2026 - 4:00PM

Hong Kong stock market

Hang Seng Index adds major Chinese chipmaker as tech pivot continues

21 Aug 2026 - 8:46PM

Hong Kong stock market

China’s tax crackdown: A-share and Hong Kong-listed firms hit hard

Beijing’s anti-tax evasion campaign could expand, raising concerns that corporate earnings, cash flows and investor sentiment may be at risk.

2 Jul 2026 - 10:22AM

BeOne Medicine's manufacturing site in Guangzhou. The company's Chinese subsidiary has agreed to pay 446 million yuan (US$65.6 million) after receiving a notice from a local tax authority. Photo: Handout

China’s private sector

Akeso lung cancer drug trial raises hopes in US$20b market

Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

1 Jun 2026 - 6:49PM

China’s private sector

China’s biotech boom drives surge in home-grown innovative drug approvals

Domestic firms dominate China’s drug approvals amid jump in spending and out-licensing deals as regulator speeds path to market.

27 May 2026 - 9:00PM

Hong Kong stock market

Hang Seng Index review to boost market capitalisation by 4.5%: analysts

Tencent, BeOne Medicines, Baidu and NetEase may lure fund inflows between US$200 million and US$1 billion, due to index weighting changes.

25 May 2026 - 4:03PMvideocam

Hong Kong regional flag, Chinese flag and HKEX flag fly outside the Exchange Square in Central. Photo: Yik Yeung-man

Hong Kong stock market

China AI firms Zhipu, MiniMax to join Hong Kong’s Hang Seng Tech Index

Additions to the benchmark Hang Seng Index, meanwhile, increase the number of constituents to 93 as the bourse operator presses ahead with expansion to 100.

22 May 2026 - 10:51PMvideocam

Made in China 2025

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

1 Mar 2026 - 12:00PM

Banking & finance

Global funds, from BlackRock to Temasek, back China’s largest biotech firms

Global institutional investors have built up sizeable positions in firms including Innovent, 3SBio, WuXi Biologics, Jiangsu Hengrui, Akeso and BeOne.

23 Jan 2026 - 8:30AM

Global investors have reaped sizeable rewards from their investments in Hong Kong-listed biotech and pharmaceutical companies in the past year. Photo: Shutterstock

China’s private sector

BeOne Medicines names R&D chief Wang Lai as president amid global expansion

BeOne generated global revenue of about US$3.8 billion last year, driven by its flagship products Brukinsa and Tevimbra.

24 Dec 2025 - 5:44PM

BeOne’s manufacturing facility in Guangzhou. Photo: Handout

Made in China 2025

China’s pharmaceutical industry transforms into a global innovation powerhouse

The China Pharmaceutical Innovation and Invention Index, a new gauge, highlights top drug makers on the mainland for the first time.

19 Dec 2025 - 8:30AM

Greater Bay Area

BeOne Medicines to expand cancer-drug offerings in Hong Kong

Fresh off a profitable half year, a global drug company that started as an R&D firm in Beijing plans to expand production in Guangzhou.

24 Oct 2025 - 11:54AM

Biomedicine: Companies

Chinese drug start-ups poised for 2025 profits, in industry milestone

Innovent likely to post a first-half net profit of US$36.4 million, and BeOne’s first-half net profit is expected to come in at US$42 million.

27 Aug 2025 - 5:25PM